US EditionPublished • loading... • Updated
Abbvie asks FDA to approve tavapadon as Parkinson’s treatment
Summary by Parkinson's News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Abbvie asks FDA to approve tavapadon as Parkinson’s treatment
Abbvie has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of tavapadon as a Parkinson’s disease treatment. Clinical data have shown that the once-daily oral small molecule appears safe, reduces motor symptoms, and prolongs periods when these symptoms are well managed. The application is based on TEMPO-1 (NCT04201093), TEMPO-2 (NCT04223193), and TEMPO-3 (NCT04542499), three Phase 3 clinical trials that te…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
